Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 14/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SLC43A1 | O75387 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13134669 | 1.00 | ABCB1 (0.38) | ABCB1TSHRKMT2ASLC43A1GAA | |
| SCHEMBL2814786 | 0.92 | NT5E (0.38) | KMT2A | |
| SCHEMBL13134599 | 0.90 | GAA (0.36) | ABCB1TSHRGAA | |
| SCHEMBL14643296 | 0.90 | GAA (0.36) | ABCB1TSHRGAA | |
| SCHEMBL13190548 | 0.87 | ABCB1 (0.41) | ABCB1TSHRKMT2ASLC43A1 | |
| SCHEMBL15160615 | 0.85 | ABCB1 (0.35) | ABCB1TSHRKMT2ASLC43A1 | |
| SCHEMBL382002 | 0.83 | ABCB1 (0.38) | ABCB1TSHRKMT2ASLC43A1 | |
| SCHEMBL779110 | 0.83 | ABCB1 (0.38) | ABCB1TSHRKMT2ASLC43A1 | |
| SCHEMBL381933 | 0.83 | ABCB1 (0.38) | ABCB1TSHRKMT2ASLC43A1 | |
| SCHEMBL2815213 | 0.82 | NT5E (0.39) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9408863-B2 | 5′-substituted nucleoside analogs and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9408863-B2 | 5′-substituted nucleoside analogs and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2016-08-09 | — | — | US | disclosed |
| US-20140221304-A1 | 5'-SUBSTITUTED NUCLEOSIDE ANALOGS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME LLC | 2014-08-07 | — | — | US | disclosed |
| US-20140221304-A1 | 5'-SUBSTITUTED NUCLEOSIDE ANALOGS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME LLC | 2014-08-07 | — | — | US | disclosed |
| WO-2013009737-A1 | 5'-SUBSTITUTED NUCLEOSIDE ANALOGS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2013-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221304-A1 | 5'-SUBSTITUTED NUCLEOSIDE ANALOGS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | NT5C3B, PNP, SLC29A1 | ABCB1 439/4885TSHR 2474/4885KMT2A 3167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.